Prevention of tumors in treating fibrocystic breast diseases using Vitex agnus-castus-based herbal remedy

Cover Page

Cite item

Full Text

Abstract

Background. Oncologists notice an increasing prevalence of female reproductive system pathological conditions that lead to benign and malignant diseases of mammary glands. Fibrocystic breast diseases (FBD) occur in approximately 80 % of women of reproductive age worldwide. Currently, there is no single widely accepted treatment for FBD. The therapy mainly includes surgery and hormonal treatment. A few herbal medicines effective against FBD include Vitex agnus-castus (VAC) medications. According to many studies, the absence of timely targeted preventive therapy puts patients with FBD at risk of developing malignant tumors. FBD is a risk factor for cancer development and turns into cancer in 3–6 % of patients.
Aim. To assess the effectiveness of VAC against FBD.
Materials and methods. In this study, 150 women aged 40+ with FBD were randomly assigned to the treatment group (n = 78) or the controls (n = 72). The groups were similar in demographic characteristics, including age, parity, menopause, history of abortions, family history of breast cancer, and alcohol and tobacco consumption. The treatment group received two tablets of VAC extract (each containing 162 mg) daily for six months. At baseline, weeks 12 and 24, all participants were evaluated using a visual analog scale and ultrasound examination.
Results. Breast pain decreased significantly in the treatment group, and the median visual analog scale scores at weeks 12 and 24 decreased significantly compared to baseline in the treatment group (89.7 % at baseline, 76.9 % at week 12, and 42.3 % at week 24) compared to the controls (66.3 % at baseline, 63.9 % at week 12 and 61.1 % at week 24). Furthermore, the breast ultrasound findings at weeks 12 and 24 revealed that regression rates in the treatment group were significantly higher than in the control arm (46.2 % vs. 6.9 % at week 12; 55.1 % vs. 8.3 % at week 24).
Conclusion. VAC is effective in managing patients with FBD. VAC treatment efficacy can be evaluated using a visual analog scale and ultrasound examination. The herbal remedy VAC extract used in this treatment for patients with FBD has proven effective in preventing breast cancer.

About the authors

N. A. Omarbayeva

Asfendiyarov Kazakh National Medical University;
Kazakh Institute of Oncology and Radiology

Author for correspondence.
Email: nazgulek87@mail.ru
ORCID iD: 0000-0002-5500-1495

Nazgul Aydarbekovna Omarbayeva 

94 Tole bi St., Almaty 050000, Republic of Kazakhstan;

91 Prospekt Abaya, Almaty 050000, Republic of Kazakhstan 

Kazakhstan

D. R. Kaidarova

Asfendiyarov Kazakh National Medical University;
Kazakh Institute of Oncology and Radiology

ORCID iD: 0000-0002-0969-5983

94 Tole bi St., Almaty 050000, Republic of Kazakhstan;

91 Prospekt Abaya, Almaty 050000, Republic of Kazakhstan 

Kazakhstan

D. Kh. Omarov

Kazakh Institute of Oncology and Radiology

ORCID iD: 0000-0001-6383-6348

91 Prospekt Abaya, Almaty 050000, Republic of Kazakhstan 

Kazakhstan

A. Askandirova

Kazakh Institute of Oncology and Radiology

ORCID iD: 0000-0002-9821-3658

91 Prospekt Abaya, Almaty 050000, Republic of Kazakhstan 

Kazakhstan

Kh. Keskin

Ankara University

ORCID iD: 0000-0003-1794-4473

Dögol Caddesi, Ankara 06100, Turkey 

Turkey

A. Zh. Abdrakhmanova

Asfendiyarov Kazakh National Medical University;
Kazakh Institute of Oncology and Radiology

94 Tole bi St., Almaty 050000, Republic of Kazakhstan;

91 Prospekt Abaya, Almaty 050000, Republic of Kazakhstan 

Kazakhstan

S. A. Yessenkulova

Asfendiyarov Kazakh National Medical University

ORCID iD: 0000-0001-5351-5188

94 Tole bi St., Almaty 050000, Republic of Kazakhstan 

Kazakhstan

T. G. Goncharova

Kazakh Institute of Oncology and Radiology

Email: goncharova.2004@mail.ru
ORCID iD: 0000-0003-2524-8750

Tatyana Georgievna Goncharova 

91 Prospekt Abaya, Almaty 050000, Republic of Kazakhstan 

Kazakhstan

A. K. Jakipbayeva

Asfendiyarov Kazakh National Medical University

94 Tole bi St., Almaty 050000, Republic of Kazakhstan 

Kazakhstan

References

  1. Kaydarova D.R., Abdrakhmanova A.Zh., Omarbaeva N.A. et al. Therapeutic effectiveness of toremifene in the treatment of dyshormonal disorders of the mammary glands. Pharmacy of Kazakhstan 2020;10:12–6. Available at: https://clck.ru/3GcEKn
  2. Malherbe K., Khan M., Fatima S. Fibrocystic Breast Disease. In: StatPearls. Treasure Island: StatPearls Publishing, 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK551609/.
  3. Rafieian-Kopaei M., Movahedi M. Systematic review of premenstrual, postmenstrual and infertility disorders of Vitex agnus-castus. Electron Physician 2017;9(1):3685–9. doi: 10.19082/3685
  4. Feng Y., Spezia M., Huang S. et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 2018;5(2): 77–106. doi: 10.1016/j.gendis.2018.05.001
  5. Egwuonwu O.A., Anyanwu S.N., Chianakwana G.U., Ihekwoaba E.C. Breast Pain: Clinical pattern and aetiology in a breast clinic in Eastern Nigeria. Niger J Surg 2016;22(1):9–11. doi: 10.4103/1117-6806.169822
  6. ElSherif A., Valente S.A. Management of mastalgia. Surg Clin North Am 2022;102(6):929–46. doi: 10.1016/j.suc.2022.06.001
  7. Csupor D., Lantos T., Hegyi P. et al. Vitex agnus-castus in premenstrual syndrome: A meta-analysis of double-blind, randomized controlled trials. Complement Ther Med 2019;47:102190. doi: 10.1016/j.ctim.2019.08.024
  8. Kulagina N.V. Treatment for mastalgia in the presence of diffuse mastopathy in female patients during the menopausal transition period. Reprod Endocrinol 2017;(38):81–5. Available at: http://reproduct-endo.com/article/view/119842/114529.
  9. Seidlova-Wuttke D., Wuttke W. The premenstrual syndrome, premenstrual mastodynia, fibrocystic mastopathy, and infertility often have common roots: Effects of extracts of chaste berry (Vitex agnus-castus) as a solution. Clin Phytosci 2017;3:6. doi: 10.1186/s40816-016-0038-z
  10. Halaska M., Beles P., Gorkow C., Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus-castus extract: Results of a placebo-controlled double-blind study. Breast 1999;8(4):175–81. doi: 10.1054/brst.1999.0039
  11. Kamal N., Mio Asni N.S., Rozlan I.N.A. et al. Traditional medicinal uses, phytochemistry, biological properties, and health applications of Vitex sp. Plants (Basel) 2022;11(15):1944. doi: 10.3390/plants11151944
  12. Mirghafourvand M., Mohammad-Alizadeh-Charandabi S., Ahmadpour P., Javadzadeh Y. Effects of Vitex agnus and Flaxseed on cyclic mastalgia: A randomized controlled trial. Complement Ther Med 2016;24:90–5. doi: 10.1016/j.ctim.2015.12.009
  13. Zeqiri A., Dermaku-Sopjani M., Sopjani M. The mechanisms underlying the role of Vitex agnus-castus in mastalgia. Bratisl Lek Listy 2022;123(12):913–8. doi: 10.4149/BLL_2022_147
  14. Breivik H., Borchgrevink P.C., Allen S.M. et al. Assessment of pain. Brit J Anaest 2008;101(1):17–24. doi: 10.1093/bja/aen103
  15. Schwartz L.H., Litière S., de Vries E. et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 2016;62:132–7. doi: 10.1016/j.ejca.2016.03.081
  16. Bernard V., Young J., Binart N. Prolactin – a pleiotropic factor in health and disease. Nat Rev Endocrinol 2019;15(6):356–65. doi: 10.1038/s41574-019-0194-6
  17. Thorat M.A., Levey P.M., Jones J.L. et al. Prognostic value of ER and PgR expression and the impact of multi-clonal expression for recurrence in ductal carcinoma in situ: Results from the UK/ANZ DCIS Trial. Clin Cancer Res 2021;27(10):2861–7. doi: 10.1158/1078-0432.CCR-20-4635

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36991 от  21.07.2009.